## Introduction

Bilateral pedal oedema (kwashiorkor) is included in the case definition of severe acute malnutrition (SAM). Current standard SAM management provides ready-to-use therapeutic food (RUTF) based on kilocalories per kilogram, thus the ration increases as the child gains weight. A prior study in SAM children comparing gradual reduction in RUTF ration to standard RUTF dosage have shown similar efficacy in children with SAM but has not specifically compared such strategies in children affected by kwashiorkor (1).

### Methods

- A secondary analysis of data of a non-inferiority randomised controlled trial in the Democratic Republic of Congo (2, 3) in children aged 6-59 months with uncomplicated oedema (+ or ++)
- Standard treatment: RUTF standard dosage (175-200 kcal/kg/j)
- OptiMA dosage: 175-200 kcal/kg/day until oedema resolved, then a decreased RUTF dosage from 175-200 to 50-166 kcal/kg/day as weight and MUAC increased
- A 6 months follow-up period post-inclusion (weekly outpatient visit during treatment then bimonthly visit at home)
- Recovery: MUAC≥125mm or WHZ≥-1.5 in the standard group and MUAC≥125mm in the OptiMA group for two consecutive weeks)
- Comparison of anthropometric changes by study arm over the six-month follow-up period by using mixed-effects generalised additive models for fitting and plotting means with IC95%.

# Optimising the dosage of ready-to-use therapeutic food in children with uncomplicated kwashiorkor: a secondary analysis of the OptiMA-DRC trial

C. Cazes<sup>1</sup>, F. Sirna<sup>1</sup>, K. Phelan<sup>2</sup>, V. Hubert<sup>3</sup>, B. Kalenga Tshiala<sup>4</sup>, G. Tshibangu Sakubu<sup>5</sup>, D. Gabillard<sup>1</sup>, S. Shepherd<sup>3</sup>, R. Becquet<sup>1</sup>

<sup>1</sup>University of Bordeaux, French National Institute for Health and Medical Research (Inserm), French National Research Institute for Sustainable Development (IRD), Bordeaux Population Health Research Center France, Team GHiGS, UMR 1219, Bordeaux; <sup>2</sup>The Alliance for International Medical Action (ALIMA), Paris, France; <sup>3</sup>The Alliance for International Medical Action (ALIMA), Dakar, Senegal; <sup>4</sup>National Nutrition Programme (PRONANUT), Ministry of Health, Kinshasa, Democratic Republic of Congo; 5Kamuesha Health Zone in the Kasaï Province, Ministry of Health, Kamuesha, Democratic Republic of Congo;





Figure 1: Panel of modelled adjusted weekly means of MUAC, WHZ WAZ and MUAC, weight and height cumulated gain through 6-month by randomisation groups (n=87)



Number of observation per week by randomisation group for MUAC, WHZ, WAZ, MUAC and weight gain cumulated parameters; Total observation 1193

## Results

- Similar baseline characteristics of the 87 children with oedema randomised (standard 49; intervention 38)
- Probability of reaching recovery by 12 weeks not significantly different between arms as well as time to recover and weight gain (+800g, p=0.84) (table1)
- The median number [cost] of RUTF sachets distributed per child was 119 sachets [USD 33] in the standard arm compared to 67 sachets [USD 19] in the intervention arm (p<0.01, (table1)</li>
- Growth curves in both groups (figure 1) were similar for all parameters over the 6-month follow-up

# Interpretation and conclusion

Episodes of uncomplicated nutritional oedema similarly resolved under both the OptiMA and standard arms, even if the RUTF ration was almost halved under the OptiMA strategy. This secondary analysis of the OptiMA-DRC trial shows for the first time that it is safe to reduce the dosage of RUTF as weight and MUAC increase among children with uncomplicated kwashiorkor with potential cost benefits.

**Acknowledgments** We are indebted to the participants, the staff of the MoH and the ALIMA operational team, the community health workers. We finally warmly thank the Innocent Foundation and the No Wasted Lives Coalition for their support.

#### References

- Kangas et al. PLOS Med. 2019 Aug 27;16(8):e1002887.
- Cazes C et al. BMJ Open. 2020 Dec 1;10(12):e041213.
- . Cazes C et al. Lancet Glob Health. 2022 Apr 1;10(4):e510–20.

Contact: cecile.cazes@coral.alima.ngo











